AstraZeneca announced positive Phase 3 results for baxdrostat, an aldosterone synthase inhibitor for treatment-resistant hypertension. The drug met primary and secondary endpoints in a late-stage trial involving 796 patients, showing a statistically significant reduction in seated systolic blood pressure with favorable tolerability. These findings validate AstraZeneca’s $1.3 billion acquisition of CinCor Pharma, which originated the candidate. The company plans to present comprehensive data at the upcoming European Society of Cardiology Congress.